WO2023067358A1 - Proteins comprising the extracellular domain of p75ntr - Google Patents
Proteins comprising the extracellular domain of p75ntr Download PDFInfo
- Publication number
- WO2023067358A1 WO2023067358A1 PCT/GB2022/052692 GB2022052692W WO2023067358A1 WO 2023067358 A1 WO2023067358 A1 WO 2023067358A1 GB 2022052692 W GB2022052692 W GB 2022052692W WO 2023067358 A1 WO2023067358 A1 WO 2023067358A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- p75ntr
- companion animal
- fusion protein
- isolated
- protein
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 83
- 102000004169 proteins and genes Human genes 0.000 title abstract description 79
- 241001465754 Metazoa Species 0.000 claims abstract description 123
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 97
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 97
- 208000002193 Pain Diseases 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 43
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 42
- 230000036407 pain Effects 0.000 claims abstract description 42
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 36
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 36
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 claims abstract description 25
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims abstract 23
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 67
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 64
- 241000282465 Canis Species 0.000 claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 59
- 238000011282 treatment Methods 0.000 claims description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 241000282472 Canis lupus familiaris Species 0.000 claims description 28
- 239000013598 vector Substances 0.000 claims description 24
- 241000283073 Equus caballus Species 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 15
- 201000008482 osteoarthritis Diseases 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 12
- 241000282326 Felis catus Species 0.000 claims description 11
- 102000007562 Serum Albumin Human genes 0.000 claims description 11
- 108010071390 Serum Albumin Proteins 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 206010017999 Gastrointestinal pain Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 208000009935 visceral pain Diseases 0.000 claims description 2
- 241000009328 Perro Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 8
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 94
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 93
- 210000004027 cell Anatomy 0.000 description 83
- 235000018102 proteins Nutrition 0.000 description 76
- 229940053128 nerve growth factor Drugs 0.000 description 57
- 102000004196 processed proteins & peptides Human genes 0.000 description 55
- 229920001184 polypeptide Polymers 0.000 description 51
- 235000001014 amino acid Nutrition 0.000 description 43
- 150000001413 amino acids Chemical class 0.000 description 41
- 241000282324 Felis Species 0.000 description 30
- 239000000243 solution Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 23
- 230000000903 blocking effect Effects 0.000 description 23
- 241000700159 Rattus Species 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 238000001990 intravenous administration Methods 0.000 description 18
- 230000037396 body weight Effects 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 12
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 12
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 12
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 208000030175 lameness Diseases 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 9
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 229940121531 bedinvetmab Drugs 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 239000012146 running buffer Substances 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 101150050927 Fcgrt gene Proteins 0.000 description 7
- 241001529936 Murinae Species 0.000 description 7
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108090000742 Neurotrophin 3 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 5
- 101100404655 Rattus norvegicus Ngf gene Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000000629 knee joint Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 201000004595 synovitis Diseases 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 4
- 230000004989 O-glycosylation Effects 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229960001929 meloxicam Drugs 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012384 transportation and delivery Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 102100029268 Neurotrophin-3 Human genes 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000012743 protein tagging Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- -1 Fc domain Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000736088 Homo sapiens PC4 and SFRS1-interacting protein Proteins 0.000 description 2
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000000585 Interleukin-9 Human genes 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102000006437 Proprotein Convertases Human genes 0.000 description 2
- 108010044159 Proprotein Convertases Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100032889 Sortilin Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102000046917 human NGF Human genes 0.000 description 2
- 102000052073 human NGFR Human genes 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 229940076264 interleukin-3 Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 229940118526 interleukin-9 Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Chemical group 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 238000007702 DNA assembly Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 108090000099 Neurotrophin-4 Proteins 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000035071 co-translational protein modification Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940124707 pain therapeutics Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000000426 patellar ligament Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006389 polyphenyl polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000009844 retrograde axon cargo transport Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 101150025395 trkA gene Proteins 0.000 description 1
- 101150113435 trkA1 gene Proteins 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Definitions
- the present invention relates to effective pain therapies in companion animals.
- Pain relief treatments for dogs currently include nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, and several nonsteroidal anti-inflammatory drugs which help to control pain and inflammation associated with osteoarthritis.
- NSAIDs nonsteroidal anti-inflammatory drugs
- Several NSAIDs have been approved by the FDA. However, there is a need for further effective pain treatments in companion animals with minimal side effects.
- Nerve growth factor was firstly discovered in 1950s. The NGF protein was then cloned and identified as part of brain-derived neurotrophic factor (BDNF), neurotrophin-3 and 4/5 (NT-3, NT-4-5). All of these are secreted proteins that promote survival and growth of the peripheral nervous system.
- BDNF brain-derived neurotrophic factor
- NT-3, NT-4-5 neurotrophin-3 and 4/5
- NGF causes peripheral sensitization both in vitro and in vivo, as illustrated by the increased response of DRG neurons to temperature or capsaicin in its presence. NGF also leads to transcriptional regulation after retrograde axonal transport, as illustrated by immunostaining showing upregulation of BDNF after intrathecal NGF treatment. Furthermore, NGF can cause sprouting of peripheral afferents into diseased joints and cancerous tissue (Denk et al, Annual Review of Neuroscience, Vol. 40:307-325, 2017).
- NGF is expressed at low levels in adulthood, but injury, inflammation or release of NGF cause activation of inflammatory cells. These cells in turn produce and secrete NGF as well and this leads to short-term and long-term effects.
- NGF has a well-known and multifunctional role in nociceptive processing, although the precise signaling pathways downstream of NGF receptor activation that mediate nociception are complex and not completely understood. The role of NGF in nociception and the generation and/or maintenance of chronic pain has led to it becoming an attractive target of pain therapeutics forthe treatment of chronic pain conditions (Barker et al, Journal of Pain Research, 2020:13 1223-1241).
- the invention is aimed at addressing a need for effective pain therapies in companion animals.
- the invention provides a pain therapy for companion animals with reduced side effects compared to anti-NGF antibody therapies.
- the proteins of the invention bind NGF which is at elevated levels in pain conditions, thus binding to excess NGF to restore normal NGF levels without completely blocking NGF signalling. Without wishing to be bound by theory, the inventors believe that this ensures a level of NGF signalling which is required for healthy functions. Furthermore, it is believed that the fusion proteins of the invention can operate at a very low dose, but are highly efficacious.
- the inventors have used an analgesic strategy to reduce, but not completely deplete, NGF in circulation.
- the Extracellular Domain (ECD) of p75 neurotrophin receptor (p75NTR) was used, fused to Fc to increase its half-life.
- p75NTR binds NGF and other brain-derived neurotrophic factors (NT3, NT4) and mediates different cellular activities.
- the invention relates to an isolated companion animal p75NTR protein or a portion thereof.
- the invention also relates to an isolated nucleic acid encoding the protein or portion thereof.
- the invention also relates to a vector comprising a nucleic acid as described above.
- the invention further relates to a host cell comprising a nucleic acid as described above.
- the invention in another aspect, relates to a fusion protein comprising an isolated companion animal p75NTR extracellular domain or portion thereof and a half-life extending moiety.
- the invention relates to a nucleic acid encoding a fusion protein as described above. In another aspect, the invention relates to a vector comprising a nucleic acid as described above.
- the invention relates to a host cell comprising a nucleic acid as described above or a vector as described above.
- the invention in another aspect, relates to a pharmaceutical composition
- a pharmaceutical composition comprising an isolated companion animal p75NTR protein as described above and herein, or a fusion protein as described above and herein.
- the invention in another aspect, relates to a method for treating an NGF-related disorder in a companion animal comprising administering an isolated companion animal p75NTR protein as described above, a fusion protein as described above and herein or a pharmaceutical composition as described above and herein.
- the invention relates to the use of an isolated companion animal p75NTR protein as described above, a fusion protein as described above or a pharmaceutical composition as described above and herein in the treatment of an NGF-related disorder in a companion animal.
- the invention relates to a method of inhibiting NGF activity in a companion animal comprising administering an isolated companion animal p75NTR protein as described above, a fusion protein as described above and herein or a pharmaceutical composition as described above and herein.
- the invention relates to a kit comprising an isolated companion animal p75NTR protein as described above, a fusion protein as described above or a pharmaceutical composition as described above and optionally instructions for use.
- Patent law e.g., they can mean “includes”, “included”, “including”, and the like; and that terms such as “consisting essentially of and “consists essentially of have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
- Figure 1 Exemplary fusion proteins (a) PetML119 and (b) PetML122.
- Figure 2 a) Sequence alignment of part of the ECD of p75NTR as used in the fusion proteins of the invention. There is a very high similarity between species:
- Canine vs Feline 1/164 (more than 99% identical);
- PetML119 Stability a) Tonset analysis. b) Thermal and chemical stress. c) Freeze and thaw stress. d) Thermal stability. e) Aggregation analysis.
- PetML119/122 canine and murine FcRN binding.
- Figure 7 NGF binding. a) PetML119 binding to human NGF. b) PetML119 to rat NGF. c) Kinetics affinity table. d) Bedinvetmab binding to human NGF. e) Kinetics affinity table.
- FIG. 8 TF-1 cell proliferation assay.
- Positive ctr TF-1 cells in RPMI media + 10% FBS + lOng/mL hNGF 3 timepoints (t 2hrs, 14d and t 7d).
- TF-1 cell proliferation assay read out.
- TF-1 cell proliferation assay read out using PetML119, PetMLI 22 and Bedinvetmab.
- Figure 9 In vivo model.
- Figure 10 Analgesic effects in vivo. a) 2 hours post IV treatment. b) 3 days post IV treatment. c) 11 days post IV treatment. d) 18 days post IV treatment.
- FIG. 1 Joint Diametre and body weight. a) Joint Diametre analysis. b) body weight analysis.
- FIG. 13 Safety analysis of PetML119/ PetMLI 22 in dogs.
- ADA Anti-Drug Antibodies
- Top (a) shows endpoint Absorbance at 650nm and 450nm using sera.
- Bottom (b) shows one phase decay fitting to estimate half-life for PetML1 19/ PetML122.
- Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein.
- the nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.
- the invention provides biological therapeutics for veterinary use, in particular fusion proteins for use in the treatment of companion animals such as dogs, cats, bovines or horses.
- the invention relates to an isolated companion animal p75NTR protein or a portion thereof.
- p75NTR protein refers to a p75NTR protein that binds NGF and/or other neurotrophins (BDNF, NT-3 and/or NT-4/5). As used herein, this means that the protein is capable of binding to NGF and inhibiting NGF biological activity and/or downstream pathway(s) mediated by NGF signalling.
- An NGF binding protein reduces NGF biological activity, including downstream pathways mediated by NGF signalling and/or reduces the amount of NGF that is in circulation and which can bind to its receptors trkA and NGFR (p75NTR).
- companion animal refers to a dog, cat or horse. In one embodiment, the companion animal is a dog. In another embodiment, the animal to be treated may be a cow or pig.
- isolated protein or polypeptide refers to a protein or polypeptide that is substantially free of other proteins or polypeptides, having different antigenic specificities. Moreover, protein or polypeptide may be substantially free of other cellular material and/or chemicals. Thus, the protein, nucleic acids and polypeptides described herein are preferably isolated. Thus, as used herein, an "isolated" protein, or polypeptide means protein or polypeptide that has been identified and separated and/or recovered from a component of its natural cell culture environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the protein or polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
- polypeptide and “protein” are used interchangeably to refer to a polymer of amino acid residues and are not limited to a minimum length.
- Peptides, oligopeptides, dimers, multimers, and the like are also composed of linearly arranged amino acids linked by peptide bonds, and whether produced biologically, recombinantly, or synthetically and whether composed of naturally occurring or non- naturally occurring amino acids, are included within this definition. Both full-length proteins and fragments thereof are encompassed by the definition.
- polypeptide encompasses a protein that includes modifications, such as deletions, additions, and substitutions (generally conservative in nature as would be known to a person in the art), to the native sequence, as long as the protein maintains the desired activity.
- Polypeptides or proteins are composed of linearly arranged amino acids linked by peptide bonds, but in contrast to peptides, have a well-defined conformation.
- Proteins as opposed to peptides, generally consist of chains of 50 or more amino acids.
- the term "peptide” as used herein typically refers to a sequence of amino acids of made up of a single chain of D- or L-amino acids or a mixture of D- and L-amino acids joined by peptide bonds. Generally, peptides contain at least two amino acid residues and are less than about 50 amino acids in length.
- amino acid herein is meant one of the 20 naturally occurring amino acids or any non- natural analogues that may be present at a specific, defined position. Amino acid encompasses both naturally occurring and synthetic amino acids. Although in most cases, when the protein is to be produced recombinantly, only naturally occurring amino acids are used.
- the isolated companion animal p75NTR protein comprises or consists of a canine, feline or bovine p75NTR protein or a portion or a variant thereof. Therefore, in one embodiment, the isolated companion animal p75NTR protein comprises or consists of SEQ ID No. 1 , 3, 5 or 36, a portion or a variant thereof or a variant of a portion.
- the p75 neurotrophin receptor p75NTR in its native form exists as a transmembrane glycoprotein.
- Family members are characterised by multiple cysteine-rich domains for ligand binding, a single transmembrane sequence extracellular domain (ECD), and a non-catalytic cytoplasmic domain.
- Endogenous soluble ECD of p75NTR is produced by regulated proteolysis by a- secretase and y- secretase that cleaves the protein near the membrane junction of the ECD. This is cleavage results in the release of the cytoplasmic domain which is free to bind NGF as a natural antagonist to NGF signalling.
- the isolated companion animal p75NTR protein or a portion thereof comprises or consists of the extracellular domain (ECD) or part thereof or a variant thereof. In one embodiment, the isolated companion animal p75NTR protein or a portion thereof comprises or consists of the extracellular domain (ECD). In one embodiment, the isolated companion animal p75NTR protein or a portion thereof comprises the extracellular domain (ECD) and additional C-terminal amino acids of the companion animal p75NTR protein adjacent to the ECD.
- the portion of the companion animal p75NTR protein may comprise the ECD and at least 1- 5 or 5-10 amino acids, e.g.
- a- secretase and y-secretase cleavage sites within the ECD are removed.
- the stalk region is removed.
- the stalk region and a- secretase and y- secretase cleavage sites within the ECD are removed.
- the isolated companion animal p75NTR extracellular domain is canine and comprises or consists of SEQ ID No. 7 or a variant thereof or a portion thereof, for example SEQ ID No. 34.
- the isolated companion animal p75NTR extracellular domain is feline and comprises or consists of SEQ ID No. 38 or a variant thereof or a portion thereof.
- the ECD of p75NTR has a stalk region (e.g. SEQ ID No. 9, canine stalk region) that is prone to O- glycosylation. Glycosylation in proteins can cause manufacturing difficulties.
- the isolated companion animal ECD may comprise deletions in the stalk region to reduce the number of O-glycosylation sites within the stalk region e.g. to form a truncated stalk region.
- a truncated stalk region may comprise any number of the amino acids of the stalk region.
- the stalk region may comprise 1-10, 1-20, 1-30 amino acids.
- the stalk region may be removed in embodiments of the fusion protein described herein.
- a portion of the ECD as used herein may be the ECD without the stalk region and 3’ sequences a- secretase and y-secretase cleavage sites (e.g. canine sequence SEQ ID No. 34).
- the isolated companion animal p75NTR is a truncated protein which has the O-glycosylation stalk region removed.
- the isolated companion animal p75NTR protein may be a variant of the wild type protein which comprises one or more amino acid modification compared to the wild type protein.
- the modification may be a substitution, deletion or addition of an amino acid.
- variant or “mutant” herein is meant a polypeptide sequence that differs from that of a wild-type sequence by virtue of at least one amino acid modification.
- substitution of an amino acid residue with another amino acid residue in an amino acid sequence of a protein or polypeptide as described herein, is equivalent to "replacing an amino acid residue” with another amino acid residue and denotes that a particular amino acid residue at a specific position in the original (e.g. wild type I germline) amino acid sequence has been replaced by (or substituted for) by a different amino acid residue. This can be done using standard techniques available to the skilled person, e.g. using recombinant DNA technology.
- amino acids are changed relative to the native (wild type I germline) sequence as found in nature in the wild type (wt), but may be made in IgG molecules that contain other changes relative to the native sequence.
- Variants of the p75NTR protein or portions thereof as used herein retain the biological function of the wild type protein, that is binding to NGFs.
- Amino acid modifications in general refer to and include substitutions, insertions and deletions, with the former being preferred in many cases.
- the variants of the invention include amino acid substitutions, and they can include any number of further modifications, as long as the function of the protein is still present, as described herein. In one embodiment, from 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 modifications are generally utilized as often the goal is to alter function with a minimal number of modifications.
- a variant polypeptide sequence will preferably possess at least about 80%, 85%, 90%, 95% or up to 98% or 99% identity to the wild-type sequences or the parent sequences. It should be noted that depending on the size of the sequence, the percent identity will depend on the number of amino acids. Variants do not include human sequences.
- protein variant or “variant protein” herein is meant a protein that differs from a wild-type protein by virtue of at least one amino acid modification.
- the parent polypeptide may be a naturally occurring or wild-type (WT) polypeptide, or may be a modified version of a WT polypeptide.
- Variant polypeptide may refer to the polypeptide itself, a composition comprising the polypeptide, or the amino sequence that encodes it.
- the variant polypeptide has at least one amino acid modification compared to the parent polypeptide, e.g. from about one to about ten amino acid modifications, and preferably from about one to about five amino acid modifications compared to the parent.
- the variant polypeptide sequence herein will preferably possess at least about 80% identity with a parent polypeptide sequence, and most preferably at least about 90% identity, more preferably at least about 95% identity. Variants do not include human sequences.
- parent polypeptide By “parent polypeptide”, “parent protein” as used herein is meant an unmodified polypeptide that is subsequently modified to generate a variant. Said parent polypeptide may be a naturally occurring polypeptide, or a variant or engineered version of a naturally occurring polypeptide. Parent polypeptide may refer to the polypeptide itself, compositions that comprise the parent polypeptide, or the amino acid sequence that encodes it.
- wild type or”WT wild type or "WT”
- wt or “native” herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations.
- a WT protein, polypeptide, Fc domain, immunoglobulin etc. has an amino acid sequence or a nucleotide sequence that has not been intentionally modified.
- the invention relates to an isolated nucleic acid encoding a companion animal p75NTR protein or a portion thereof, e.g. the ECD or a portion thereof or a variant.
- a portion of p75NTR or a portion of the ECD of p75NTR includes at least one neurotrophin binding domain.
- the companion animal is a dog.
- the isolated nucleic acid comprises or consists of SEQ ID No. 2, 4, 6, 8 or 37 or a variant thereof or a portion thereof.
- isolated nucleic acid molecule means a DNA or RNA of genomic, mRNA, cDNA, or synthetic origin or some combination thereof which is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature or is linked to a polynucleotide to which it is not linked in nature.
- the invention relates to a vector, plasmid, transcription, expression cassette or nucleic acid construct comprising a nucleic acid encoding a companion animal p75NTR protein or a portion thereof, e.g. the ECD or portion thereof as described above.
- the construct may include a suitable leader sequence.
- the term leader sequence is used interchangeably with signal sequence.
- the nucleic acid sequence I nucleic acid construct encoding the fusion protein may also comprise a leader sequence.
- the leader sequence is made as part of the protein and then cleaved off when the protein is secreted.
- Any suitable leader sequence may be used, including a native immunoglobulin germline leader sequence, such as the endogenous p75 leader of the relevant species (e.g. canine, equine, feline, bovine), the endogenous p75 leader of a different species e.g. human, canine, equine, feline, bovine or a mouse IgG leader or another leader sequences known in the art, e.g. the Campath leader sequence (see US 8,362,208 B2) or an artificial sequence.
- Such leader sequences can aid in enhancing protein expression.
- the invention relates to a host cell comprising a nucleic acid encoding a companion animal p75NTR protein or a portion thereof, e.g. the ECD, or a vector, plasmid, vector, transcription, expression cassette or construct as described above.
- Expression vectors of use in the invention may be constructed from a starting vector such as a commercially available vector. After the vector has been constructed and the nucleic acid molecule has been inserted into the proper site of the vector, the completed vector may be inserted into a suitable host cell for amplification and/or polypeptide expression.
- vector means a construct, which is capable of delivering, and in some aspects expressing one or more gene(s) or sequence(s) of interest in a host cell.
- vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.
- the invention also relates to an isolated recombinant host cell comprising one or more nucleic acid molecule plasmid, vector, transcription or expression cassette as described above.
- the transformation of an expression vector into a selected host cell may be accomplished by well-known methods including transfection, infection, calcium phosphate co-precipitation, electroporation, microinjection, lipofection, DEAE-dextran mediated transfection, or other known techniques. The method selected will in part be a function of the type of host cell to be used.
- the host cell may be eukaryotic or prokaryotic, for example a bacterial, viral, plant, fungal, mammalian or other suitable host cell.
- the cell is an E. coli cell.
- the cell is a yeast cell.
- the cell is a Chinese Hamster Ovary (CHO) cell, HeLa cell or other cell that would be apparent to the skilled person.
- Mammalian cell lines available as hosts for expression are well known in the art and include, but are not limited to, immortalized cell lines available from the American Type Culture Collection (ATCC) and any cell lines used in an expression system known in the art can be used to make the recombinant polypeptides of the invention.
- ATCC American Type Culture Collection
- host cells are transformed with a recombinant expression vector that comprises DNA encoding a protein.
- host cells that may be employed are prokaryotes, yeast or higher eukaryotic cells.
- Prokaryotes include gram negative or gram-positive organisms, for example E. coli or bacilli.
- Higher eukaryotic cells include insect cells and established cell lines of mammalian origin.
- suitable mammalian host cell lines include the COS-7 cells, L cells, CI27 cells, 3T3 cells, Chinese hamster ovary (CHO) cells, or their derivatives and related cell lines which grow in serum free media, HeLa cells, BHK cell lines, the CVIIEBNA cell line, human embryonic kidney cells such as 293, 293 EBNA or MSR 293, human epidermal A431 cells, human Colo205 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HL-60, U937, HaK or Jurkat cells.
- mammalian cell lines such as HepG2/3B, KB, NIH 3T3 or S49, for example, can be used for expression of the polypeptide when it is desirable to use the polypeptide in various signal transduction or reporter assays.
- suitable host cells include insect cells, using expression systems such as baculovirus in insect cells, plant cells, transgenic plants and transgenic animals, and by viral and nucleic acid vectors.
- yeasts include S. cerevisiae, S. pombe, Kluyveromyces strains, Pichia pastoris, Candida, or any yeast strain capable of expressing heterologous polypeptides.
- Suitable bacterial strains include E. coli, B. subtilis, S. typhimurium, or any bacterial strain capable of expressing heterologous polypeptides. If the protein is made in yeast or bacteria, it may be desirable to modify the product produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain a functional product. Such covalent attachments can be accomplished using known chemical or enzymatic methods.
- a host cell when cultured under appropriate conditions, can be used to express a protein that can subsequently be collected from the culture medium (if the host cell secretes it into the medium) or directly from the host cell producing it (if it is not secreted).
- the selection of an appropriate host cell will depend upon various factors, such as desired expression levels, polypeptide modifications that are desirable or necessary for activity (such as glycosylation or phosphorylation) and ease of folding into a biologically active molecule.
- the invention also relates to the use of an isolated companion animal p75NTR protein or a portion thereof as described above in a fusion protein with another moiety, e.g. with a half-life extending moiety as described in more detail below. Therefore, the p75NTR protein or a portion thereof can be provided covalently linked or couple to a half-life extending moiety. Alternatively, it may be provided incorporated in a liposome.
- the invention further relates to an isolated companion animal p75NTR protein or a portion thereof for use in therapy. Further, there is provided an isolated companion animal p75NTR protein or a portion thereof for use in the treatment of a pain related disease. Such diseases are described in more detail below.
- the half-life of the p75NTR protein is extended.
- the invention relates to a fusion protein comprising an isolated companion animal p75NTR protein or portion thereof, e.g. the extracellular domain, as described above and another moiety.
- the other moiety may be a half-life extending moiety.
- the p75NTR protein or portion thereof is coupled to a half-life extending moiety.
- the p75NTR protein or portion thereof may be canine, feline or equine.
- the p75NTR protein or portion thereof used in the fusion protein may thus comprise or consist of a sequence selected from SEQ ID NO. 1 , 3, 5, 7, 34, 36 or 38 or a portion or a variant thereof.
- the stalk region e.g. SEQ ID NO. 9 is removed.
- the half-life extending moiety may be selected from the following non-limiting list: a companion animal immunoglobulin Fc domain, polyethylene glycol (PEG), PEG derivatives, simple lipids, lipid dicarboxylic acids, lipids with additional moieties, companion animal serum albumin binders, e.g. small-molecule binders or antibodies/antibody fragments that bind companion animal serum albumin, companion animal serum albumin, or streptococcal protein G’s albumin-binding domain (ABD).
- companion animal serum albumin binders e.g. small-molecule binders or antibodies/antibody fragments that bind companion animal serum albumin, companion animal serum albumin, or streptococcal protein G’s albumin-binding domain (ABD).
- lipids include glucagon-like peptide 1 (GLP-1), the analogs GLP-1 liraglutide and semaglutide or cholesterol.
- an immunoglobulin Fc domain facilitates purification of the protein.
- Fc binding to Protein A can be used in purification procedures.
- the presence of an immunoglobulin Fc domain can also stabilise the overall folding of the fusion protein as well as extending its half-life.
- the half-life extending moiety is a companion animal Fc domain, companion animal serum albumin binder or companion animal serum albumin
- the p75NTR protein or portion and half-life extending moiety are from I specific to the same companion animal.
- the half-life extending moiety is a companion animal Fc domain of the corresponding companion animal.
- the p75NTR protein or portion thereof e.g.
- the Fc domain is canine. If the p75NTR protein or portion thereof, e.g. the extracellular domain is feline, the Fc domain is feline. If the p75NTR protein or portion thereof, e.g. the extracellular domain is equine, the Fc domain is equine. If the p75NTR protein or portion thereof, e.g. the extracellular domain is bovine, the Fc domain is bovine.
- the half-life extending moiety is a companion animal Fc domain, companion animal serum albumin binder or companion animal serum albumin
- the p75NTR protein or portion and half-life extending moiety are not from I specific to the same companion animal.
- the half-life extending moiety is the companion animal Fc domain of the corresponding companion animal, but the p75 protein or portion thereof is that of a different companion animal.
- the Fc domain is canine
- the p75NTR protein or portion thereof, e.g. the extracellular domain is may be from a different animal, e.g. cat, horse or cow.
- the p75NTR protein or portion thereof, e.g. the extracellular domain is may be from a different animal, e.g. dog, cow or horse.
- the p75NTR protein or portion thereof, e.g. the extracellular domain is may be from a different animal, e.g. cat, cow dog.
- human p75 or a portion thereof fused to companion animal Fc can be used.
- the companion animal serum albumin binder e.g. antibody or fragment thereof, may be canine or caninized, feline of felinized, equine or equinized.
- the companion animal serum albumin binder may bind to canine, feline or equine serum albumin.
- the half-life extending moiety is a wild type or variant Fc domain.
- the term variant is as defined above.
- an Fc domain variant may have modified half-life compared to the wild type Fc domain.
- the Fc domain is a canine Fc domain, that is a wild type domain or a variant thereof.
- Variant Fc domains are described, for example in W02020/142625.
- Fc or “Fc region” or “Fc domain” as used herein is meant the polypeptide comprising the constant region of an antibody excluding the first constant region immunoglobulin domain (CH1) and, in some cases, part of the hinge.
- the Fc domain includes constant region immunoglobulin domains CH2, CH3 and the hinge region between CH1 and CH2 or part of the hinge region.
- Fv fragment variable
- Fab fragment antigen binding
- Fc fragment crystallisation
- the Fc fragment comprises the carboxyterminal portions of both H chains held together by disulfides.
- the constant domains of the Fc fragment are responsible for mediating the effector functions of an antibody.
- IgG heavy chains there are four IgG heavy chains referred to as A, B, C, and D. These heavy chains represent four different subclasses of dog IgG, which are referred to as IgG-A, IgG-B, IgG-C and IgG-D.
- the DNA and amino acid sequences of these four heavy chains were first identified by Tang et al. (Vet. Immunol. Immunopathol. 80: 259-270 (2001)).
- Exemplary amino acid and DNA sequences for these heavy chains are also available from the GenBank data bases (IgGA: accession number AAL35301.1 , IgGB: accession number AAL35302.1 , IgGC: accession number AAL35303.1 , IgGD: accession number AAL35304.1). Amino acid sequences for IgG-A, IgG-B, IgG-C and IgG-D as used by the inventors and according to the aspects and embodiments of the invention are provided as SEQ ID Nos. 15, 16, 17, 18).
- Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains.
- Fc may include the J chain.
- the Fc domain comprises immunoglobulin domains CH2 and CH3 and the lower hinge region between CH1 and CH2.
- the human IgG heavy chain Fc region is usually defined to include residues C226 or P230 to its carboxyl- terminus, wherein the numbering is according to the EU index as in Kabat.
- Fc as used herein may refer to the Fc region in isolation, or this region in the context of an Fc fusion ("fusion composition” or “fusion construct”), as described herein.
- Fc domains include all or part of an Fc region; that is, N- or C- terminal sequences may be removed from wild-type or variant Fc domains, as long as this does not affect function.
- IgG functions are generally achieved via interaction between the Fc region of the Ig and an Fey receptor (FcyR) or another binding molecule, sometimes on an effector cell. This can trigger the effector cells to kill target cells to which the antibodies are bound through their variable (V) regions. Also, antibodies directed against soluble antigens might form immune complexes which are targeted to FcyRs which result in the uptake (opsonisation) of the immune complexes or in the triggering of the effector cells and the release of cytokines.
- FcyR Fey receptor
- V variable
- antibodies directed against soluble antigens might form immune complexes which are targeted to FcyRs which result in the uptake (opsonisation) of the immune complexes or in the triggering of the effector cells and the release of cytokines.
- Fc gamma receptor any member of the family of proteins that bind the IgG antibody Fc region and is encoded by an FcyR gene.
- FcyR any member of the family of proteins that bind the IgG antibody Fc region and is encoded by an FcyR gene.
- FcyR three classes of FcyR have been characterised, although the situation is further complicated by the occurrence of multiple receptor forms. The three classes are:
- FcyRI CD64 including isoforms FcyRla, FcyRIb, and FcyRIc binds monomeric IgG with high affinity and is expressed on macrophages, monocytes, and sometimes neutrophils and eosinophils;
- FcyRII (CD32) binds complexed IgG with medium to low affinity and is widely expressed.
- These receptors can be divided into two important types, FcyRlla and FcyRllb.
- the 'a' form of the receptor is found on many cells involved in killing (e. g. macrophages, monocytes, neutrophils) and seems able to activate the killing process and occurs as two alternative alleles.
- the 'b' form seems to play a role in inhibitory processes and is found on B-cells, macrophages and on mast cells and eosinophils. On B- cells it seems to function to suppress further immunoglobulin production and isotype switching to for example, the IgE class.
- the b form acts to inhibit phagocytosis as mediated through FcyRlla.
- the b form may help to suppress activation of these cells through IgE binding to its separate receptor and
- FcyRIII (CD16) binds IgG with medium to low affinity and exists as two types. FcyRllla is found on NK cells, macrophages, eosinophils and some monocytes and T cells and mediates ADCC. FcyRlllb is highly expressed on neutrophils. Both types have different allotypic forms.
- Canine Fc receptors are described in Bergeron et al L.M. Bergeron et al.; Veterinary Immunology and Immunopathology 157 (2014) 31- 41 .
- Canine has Rl, Rllb, Rill, but not Riia.
- IgG antibodies can activate complement and this can also result in cell lysis, opsonisation or cytokine release and inflammation.
- the Fc region also mediates such properties as the transportation of IgGs to the neonate (via the so-called "FcRn"), increased half-life (also believed to be effected via an FcRn-type receptor) and self-aggregation.
- the Fc-region is also responsible for the interaction with protein A and protein G (which interaction appears to be analogous to the binding of FcRn).
- effector function as used herein is meant a biochemical event that results from the interaction of an antibody Fc region with an Fc receptor or ligand. Effector functions include but are not limited to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC).
- ADCC antibody-dependent cell-mediated cytotoxicity
- ADCP antibody-dependent cell-mediated phagocytosis
- CDC complement-dependent cytotoxicity
- the companion animal p75NTR protein or portion thereof, e.g. the extracellular domain, and the other moiety are linked with a linker moiety or otherwise conjugated, attached or covalently or non-covalently linked.
- Suitable linkers are known to the skilled person.
- the linker is a peptide linker, such as a glycine and/or alanine and/or threonine and/or serine-rich linker e.g. a glycine-serine linker, such as (G4S) n wherein n is 1 to 4.
- the linker can be cleavable.
- the companion animal p75NTR protein or portion thereof comprises or consists of a canine p75NTR ECD or portion thereof.
- the ECD comprises of consists of SEQ No. 7 or a variant thereof.
- the invention relates to a fusion protein comprising a canine p75NTR ECD linked to a canine Fc domain.
- the ECD comprises of consists of SEQ No. 7 or a variant thereof.
- the fusion protein of the present invention preferably binds to any one or more of NGF, BDNF, NT3 or NT4/5 with a binding affinity (Kd) of between about IpM to about 100 nM.
- the binding affinity (Kd) is between about 5pM and any of about 10 pM, 20pM, 40pM, 50pM lOOpM, 0.2nM, 0.5nM, InM 1.5nM 2 nM, 2.5 nM, 3 nM, 3.5 nM, 4 nM, 4.5 nM, 5 nM, 5.5 nM, 6 nM, 6.5 nM, 7 nM, 7.5 nM, 8 nM, 8.5 nM, 9 nM, 9.5 nM, 10 nM, 15 nM, 20 nM, 25 nM, 30 nM, 35 nM, 40 nM, 45 nM, 50 nM or 100 nM
- the fusion protein comprises or consists of SEQ ID NO. 11 or 13 or a variant thereof.
- These fusion proteins include the p75 ECD operably linked to a canine Fc domain as shown in Figure 1 .
- the Fc domain in the construct of SEQ ID NO. 11 is a wild type canine Fc domain.
- the Fc domain in the construct of SEQ ID NO. 13 is a variant canine Fc domain which has been modified to increase halflife. In this domain, the mutation YTE has been introduced at residues Y252 - T254 -of the wt Fc domain using EU numbering.
- the fusion protein comprises or consists of SEQ ID NO. 39.
- Such a fusion proteins includes the p75 ECD operably linked to a feline Fc domain.
- the Fc domain in the construct of SEQ ID NO. 39 is a wild type feline Fc domain.
- modified companion animal Fc domains that include this mutation, e.g. canine, feline or equine Fc domains, can be used in the fusion proteins of the invention.
- a skilled person would know that any other known mutations that increase half-life could also be introduced in the Fc domain.
- the fusion proteins demonstrate advantageous biological properties including improved solubility, stability and/or improved serum half-life.
- Improved solubility and stability is, for example, demonstrated in Examples 4 and 9. These examples show that the described molecules are very stable in both temperature and chemical stress, showing unfolding only when incubated at temperature higher than 70°C with no aggregation up to 95°C with Tm1 around 67°C.
- Improved half-life is, for example, demonstrated in Examples 11 and 12. Improved half-life allows for less frequent dosing (a single administration in comparison to existing treatments where daily administration is required). This effect is demonstrated whilst showing strong analgesic effects.
- the fusion protein of the invention has a half-life in-vivo of about or more than any one of 2, 4, 6, 8,10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 1 10, 1 12, 1 14, 1 16, 1 18, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152,154, 156, 158, 160, 62, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 19
- the fusion protein of the invention has a half-life in-vitro of about or more than any one of 2, 4, 6, 8,10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104,
- the fusion protein has a half-life in-vitro of about or more than 6 days or more than 1 month. In one embodiment, the half life is 14 days.
- the in-vivo half-life can be the half-life in rat or in the corresponding companion animal, e.g. in a dog.
- Fusion proteins of the invention can operate at a very low dose, but are highly efficacious. This is, for example, demonstrated in Examples 11 and 12 where administration of PetML119 and PetML122 in rats and dogs outcompete existing treatments.
- the fusion proteins display a good safety profile. This is, for example, demonstrated in Example 12, where animals maintain normal body weight and haematological parameters and do not generate anti-Drug Antibodies after administration of fusion proteins. The maintenance of normal body weight after administration is, for example, also demonstrated in Example 11 . This is in contrast to the administration of dexamethasone which decreased body weight over time.
- the invention relates to an isolated nucleic acid encoding a fusion protein as described above, for example a fusion protein encoding SEQ ID NO. 11 ,13 or 39.
- the nucleic acid is selected from SEQ ID NO. 12, 14 or 40.
- the invention relates to a vector, plasmid, vector, transcription, expression cassette or construct comprising a nucleic acid described above.
- the invention relates to a host cell comprising a nucleic acid vector, plasmid, vector, transcription, expression cassette or construct as described above. Suitable host cells are described elsewhere herein.
- the P75NTR protein, portion thereof or fusion protein is labelled with a detectable or functional label.
- a label can be any molecule that produces or can be induced to produce a signal, including but not limited to fluorophores, fluorescers, radiolabels, enzymes, chemiluminescers, a nuclear magnetic resonance active label or photosensitizers.
- the binding may be detected and/or measured by detecting fluorescence or luminescence, radioactivity, enzyme activity or light absorbance.
- a pharmaceutical composition comprising a p75NTR protein or portion thereof or a fusion protein of the invention.
- the fusion protein or pharmaceutical composition described herein can be administered by any convenient route, including but not limited to oral, topical, parenteral, sublingual, rectal, vaginal, ocular, intranasal, pulmonary, intradermal, intravitrial, intratumoural, intramuscular, intraperitoneal, intravenous, subcutaneous, intracerebral, transdermal, transmucosal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin or by inhalation.
- delivery is of the nucleic acid encoding the drug, e.g. a nucleic acid encoding the molecule of the invention is delivered.
- Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravesical, intradermal, topical, intra-articular or subcutaneous administration.
- the compositions are administered parenterally.
- the pharmaceutically acceptable carrier or vehicle can be particulate, so that the compositions are, for example, in tablet or powder form.
- carrier refers to a diluent, adjuvant or excipient, with which a drug antibody conjugate of the present invention is administered.
- Such pharmaceutical carriers can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- the carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like.
- auxiliary, stabilizing, thickening, lubricating and coloring agents can be used.
- the polypeptide of the present invention or compositions and pharmaceutically acceptable carriers are sterile.
- Water is a preferred carrier when the drug antibody conjugates of the present invention are administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- the present compositions if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- the pharmaceutical composition can be in the form of a liquid, e.g., a solution, syrup, solution, emulsion or suspension.
- the liquid can be useful for oral administration or for delivery by injection, infusion (e.g., IV infusion) or sub-cutaneous.
- composition When intended for oral administration, the composition can be in solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
- the composition can be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form.
- a solid composition typically contains one or more inert diluents.
- binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, corn starch and the like; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
- a liquid carrier such as polyethylene glycol
- a composition When intended for oral administration, a composition can comprise one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer.
- a surfactant In a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.
- compositions can take the form of one or more dosage units.
- composition can be desirable to administer the composition locally to the area in need of treatment, or by intravenous injection or infusion.
- the amount of the polypeptide, Fc domain or pharmaceutical composition described herein that is effective/active in the treatment of a particular disease or condition will depend on the nature of the disease or condition and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disease, and should be decided according to the judgment of the practitioner and each patient's circumstances. Factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account.
- the amount is at least about 0.01 % of a polypeptide of the present invention by weight of the composition. When intended for oral administration, this amount can be varied to range from about 0.1 % to about 80% by weight of the composition.
- Preferred oral compositions can comprise from about 4% to about 50% of the polypeptide of the present invention by weight of the composition.
- compositions can be prepared so that a parenteral dosage unit contains from about 0.01 % to about 2% by weight of the polypeptide of the present invention.
- the composition can comprise from about typically about 0.1 mg/kg to about 250 mg/kg of the animal's body weight, preferably, between about 0.1 mg/kg and about 20 mg/kg of the animal's body weight, and more preferably about 1 mg/kg to about 10 mg/kg of the animal's body weight.
- the composition is administered at a dose of about 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg.
- the dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks or more.
- Treatment can for example be once a month or bi-monthly. This is advantageous over daily administration as this improves compliance and minimises stress to the animal.
- treat means inhibiting or relieving a disease or disease.
- treatment can include a postponement of development of the symptoms associated with a disease or disease, and/or a reduction in the severity of such symptoms that will, or are expected, to develop with said disease.
- the terms include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of such symptoms.
- the terms denote that a beneficial result is being conferred on at least some ofthe mammals, e.g., canine patients, being treated. Many medical treatments are effective for some, but not all, patients that undergo the treatment.
- subject or “patient” refers to an animal which is the object of treatment, observation, or experiment, suitably a companion animal, specifically a canine or a feline.
- the invention relates to the use of a p75NTR protein or portion thereof, fusion protein or pharmaceutical composition described herein in the treatment or prevention of a disease.
- the disclosure relates to the use of a polypeptide, Fc domain or pharmaceutical composition described herein in the manufacture of a medicament for the treatment or prevention of a disease as listed herein.
- the invention further relates to a method of treating a disease in a subject comprising an effective amount of the polypeptide, Fc domain or pharmaceutical composition as described herein to said subject.
- the disease is a NGF related disorder.
- the NGF related disorder is selected from the group consisting of: cardiovascular diseases, atherosclerosis, obesity, type 2 diabetes, metabolic syndrome, pain and inflammation.
- the NGF related disorder comprises pain.
- the pharmaceutical composition is used in the treatment of pain.
- the pharmaceutical composition is used for the treatment of a pain and the type of pain is selected from osteoarthritis pain, rheumatoid arthritis pain, surgical and postsurgical pain, incisional pain, general inflammatory pain, cancer pain, pain from trauma, neuropathic pain, neuralgia, diabetic neuropathy pain, pain associated with rheumatic diseases, pain associated with musculoskeletal diseases, visceral pain, and gastrointestinal pain.
- the pain comprises osteoarthritis pain.
- the pain comprises surgical and post-surgical pain.
- the pain comprises cancer pain.
- the p75NTR protein or portion thereof, fusion protein or pharmaceutical composition of the invention is for use in a canine. In one or more embodiments, the p75NTR protein or portion thereof, fusion protein or pharmaceutical composition of the invention is for use in felines. In one or more embodiments, the p75NTR protein or portion thereof, fusion protein or pharmaceutical composition of the invention is for use in equine.
- the p75NTR protein or portion thereof, fusion protein or pharmaceutical composition of the invention is administered together with one or more therapeutic agent, for example a therapeutic agent to treat pain.
- polypeptide, the p75NTR protein or portion thereof, fusion protein or pharmaceutical composition may be administered at the same time or at a different time as the other therapy or therapeutic compound or therapy, e.g., simultaneously, separately or sequentially.
- the invention also provides an in vitro or in vivo method for inhibiting NGF activity in a companion animal comprising administering the p75NTR protein or portion thereof, fusion protein or pharmaceutical composition of the invention.
- the present invention provides a method of producing the fusion protein of the invention by culturing the host cell of the invention under conditions that result in production of the fusion protein and subsequently isolating the fusion protein from the host cell or culture medium of the host cell.
- the invention provides a kit for the treatment or prevention of a disease, diagnosis, prognosis or monitoring disease comprising a the p75NTR protein or portion thereof, fusion protein or pharmaceutical composition of the invention of the invention.
- a kit may contain other components, packaging and/or instructions.
- the invention in another aspect provides a the p75NTR protein or portion thereof, fusion protein or pharmaceutical composition of the invention packaged in lyophilized form or packaged in an aqueous medium.
- a p75NTR protein or portion thereof, fusion protein or pharmaceutical composition of the invention as described herein is used for non-therapeutic purposes, such as diagnostic tests and assays.
- the present invention also provides the above p75NTR proteins and fusion proteins for use in diagnostic methods for detecting NGF in species, particularly canines and felines, known to be or suspected of having an NGF related disorder.
- Methods for detecting NGF in species, particularly canines and felines, known to be or suspected of having an NGF related disorder may include exposing a sample from the animal to a labelled protein of the invention and detecting said labelled protein, may be used to quantitatively or qualitatively detect the NGF in a sample or to detect presence of cells that express the NGF.
- DNA constructs were generated to encode chimeric Fc fusion protein comprising selected canine IgG constant regions (between hinge and C-terminus) fused to the extracellular domain of canine p75 lacking the predicted O-glycosylation rich stalk region and the a- and y-secretase sites.
- the amino acid sequences for PetML119 (SEQ ID NO: 1 1) and PetML122 (SEQ ID NO: 13) are given in Figure 1.
- An alignment of canine, feline, bovine and equine p75 sequence portions is provided in Figure 2.
- Both the canine IgG-B Fc domain and the p75 extracellular domain were codon optimised and synthesised by GeneArt (Thermo Fisher). Both genes were PCR amplified using Q5 high fidelity DNA polymerase (using specific primers including overlapping regions to allow assembly) and assembled into mammalian expression vector PetML1 19 (Fc-Bwt) and PetML122 (Fc-B-YTE with the mutated residues Y252 - T254 - E256 using EU numbering) using NEBuilder HIFI DNA Assembly (New England Biolabs).
- the fusion protein chain and the antibiotic resistant gene expression units are flanked by DNA transposon piggyBac terminal inverted repeats to mediate stable integration into host cells in the presence of piggyBac transposase.
- Both expression vectors also contain puromycin resistant cassette which is located within the piggyBac terminal repeats to facilitate selection for stable integration.
- PetML1 19 or PetMH 22 was transfected into a suitable mammalian cell line such as CHO cells together with PiggyBac transposase followed by puromycin selection at 10-30 pg/ml for at least 8-10 days.
- Neutralised fusion protein pooled fractions were concentrated till 5mL and loaded into PBS preequilibrated HiLoad 16/600 Superdex 200 pg (28989335) as second step purification. Monomeric fractions (based on previously analysed protein standards’ retention times) were pooled and protein concentration was assessed using NanoDropTM One (Thermo ScientificTM).
- PetML119 showed 34mg/L final recovery after two step purification (with acceptable Endotoxin and HCP using standard protocols and buffers).
- PetML122 showed 28mg/L final recovery after two step purification (with acceptable Endotoxin and HCP using standard protocols and buffers)
- HPLC-SCX chromatography (column: BioResolve SCX mAb Column, 3 pm, 4.6 mm x 100 mm) was performed using ACQUITY H-class Bio from WATERS using MES pH5 as mobile phase with salt gradient used to separate charge variants at 0.9mL/min flow rate.
- PetML1 19/122 showed very high purity (more than 99%) by HSEC and few charge variants (potentially corresponding to different glycoforms) were observed by HSCX.
- PetML119 showed good resistance to Freeze and Thaw, with only minor protein loss upon 3 cycles.
- Purified fusion proteins (PetML119 and PetML122) in PBS were concentrated using centrifugal concentrators (Sartorious - VS02H22) to 5mg/mL Protein concentration was assessed using UV absorbance at 280nm with NanoDropTM One (Thermo ScientificTM).
- Binding affinity of fusion proteins to Protein A was assessed using Biacore 8K (Cytiva).
- Sensor Chip Protein A (Cytiva) was docked into Biacore 8K, equilibrated for 30’ at RT and then Running Buffer (10mM HEPES pH7.4 150mM NaCI 3mM EDTA and 0.005% Tween20) was applied to the SPR chip surface.
- Fusion protein dilutions were prepared diluting PetML119/122 from 1 uM to 4nM (6 concentrations with 1 :3 dilutions) in Running Buffer and kinetics was assessed using single cycle kinetics method (Biacore Assay Handbook, Cytiva). Kinetics and/or Affinity quantification have been performed using Biacore Insight following standard analyses methods. The results show that protein A binding for PetML122 is slightly affected by YTE mutation introduced, a faster dissociation is observed compared to PetML119. This results in lower yield post protein A purification although the quality of protein is comparable.
- Purified fusion proteins (PetML1 19 and PetML122) in PBS were concentrated using centrifugal concentrators (Sartorious - VS02H22) to 5mg/mL Protein concentration was assessed using UV absorbance at 280nm with NanoDropTM One (Thermo ScientificTM).
- Binding affinity of fusion proteins to Fc Neonatal Receptor was assessed using Biacore 8K (Cytiva).
- CM5 Sensor Chip (Cytiva) was docked into Biacore 8K, equilibrated for 30’ at RT and then Running Buffer (10mM HEPES pH6 150mM NaCI 3mM EDTA and 0.005% Tween20) was applied to the SPR chip surface.
- Canine and murine FcRn-B2M recombinant protein (Immunitrack, ITF12 - ITF08) was diluted into 10mM acetate buffer pH4.5 at 4nM (1 :2000 dilution from stock) and immobilised using standard amine coupling reaction
- Fusion protein dilutions were prepared from 3uM to 37nM (5 concentrations with 1 :3 dilutions) in Running Buffer and kinetics was assessed using multi-cycle kinetics method (120sec association - 300sec dissociation). Kinetics and/or Affinity quantification have been performed using Biacore Insight following standard analyses methods.
- Purified fusion protein (PetML119) in PBS was concentrated using centrifugal concentrators (Sartorious - VS02H22) to 5mg/mL Protein concentration was assessed using UV absorbance at 280nm with NanoDropTM One (Thermo ScientificTM).
- Binding affinity of fusion proteins to human and rat NGF was assessed using Biacore 8K (Cytiva).
- Protein A Sensor Chip (Cytiva) was docked into Biacore 8K, equilibrated for 30’ at RT and then Running Buffer (10mM HEPES pH7.4 150mM NaCI 3mM EDTA and 0.005% Tween20) was applied to the SPR chip surface.
- PetML1 19 was diluted into running buffer at 6nM concentration. These have been immobilised using 90sec association at 10uL/min as capturing step, followed by injection of running buffer to remove any unbound product.
- Human and rat NGF (from Bio-Techne Ltd - 556-NG/CF / 256-GF-100/CF) was diluted in Running Buffer at 10OnM with 1 :2 further dilutions down to 4.68nM.
- Kinetics were assessed using multi-cycle kinetics with capture step method (30sec association - 120sec dissociation) followed by regeneration step (0.1 M Glycine pH2.2 contact time 60sec FR 30uL/min). Kinetics quantification have been performed using Biacore Insight following standard analyses methods.
- Results showed subnanomolar KD for both human and rat NGF with PetML119.
- Purified fusion proteins (PetML1 19 and PetML122) in PBS were concentrated using centrifugal concentrators (Sartorious - VS02H22) to 1 mg/mL Protein concentration was assessed using UV absorbance at 280nm with NanoDropTM One (Thermo ScientificTM).
- the intact molecule appears to be a mixture of species.
- the observed mass is 96158-97836 Da.
- the mass of the base species (96158Da) is consistent with a dimer of Fc fusion aa 20-241 + 4 glycans which is consistent with the total number of glycosylation sites expected in the molecule. Additional species are consistent with additional decoration of the glycans.
- Purified fusion proteins (PetML119) in PBS were concentrated using centrifugal concentrators (Sartorious - VS02H22) to 3mg/mL Protein concentration was assessed using UV absorbance at 280nm with NanoDropTM One (Thermo ScientificTM).
- TF-1 cell line To assess biological activity of our p75 fusion protein, we used an NGF-dependent (cell line TF-1 cell line). The cells are completely dependent on interleukin 3 (IL-3) or granulocyte-macrophage colonystimulating factor (GM-CSF) for long term growth. The cells do not respond to interleukin 5 (IL- 5).
- TF-1 cells respond to a variety of other lymphokines and cytokines such as interleukin 1 (IL-1), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 9 (IL-9), Interleukin 11 (IL-11), interleukin 13 (IL-13), stem cell factor (SCF), leukemia inhibitory factor (LIF) and nerve growth factor (NGF).
- IL-1 interleukin 1
- IL-4 interleukin 4
- IL-6 interleukin 6
- IL-9 Interleukin 9
- IL-11 Interleukin 11
- IL-13 interleukin
- TF-1 cell line was bought from ATCC (CRL-2003) and kept in culture using standard aseptic methods using complete RPMI (10% FBS + 2mM l-GIn + l Ong/mL hNGF).
- TF-1 cells 2 million TF-1 cells were labelled with 2.5uM CFSE cell trace (Invitrogen - C34554) in 1 mL of RPMI only for 30’ at RT in the dark. Cells have been then washed 2x in complete RPMI media, counted again and seeded at 10000cells/mL (1 mL total volume per well) in 24-well plate.
- Plates were analysed after 3 days. Briefly, 1 mL cell suspension were centrifuged 5’ at 300g RT, washed 2times with FACS buffer (PBS + 3% FBS + 3mM EDTA) and finally resuspended in 100uL of FACS buffer. Cells were acquired using CytoFLEX Flow Cytometer using following parameters (FSC:20 ; SSC:50 ; FITC:1 ; threshold: 1313131). Cells were gated based on FITC fluorescence (more fluorescence less proliferation) and % of proliferation inhibition was calculated considering 100% inhibition TF-1 cells cultured in RPMI without NGF and 0% inhibition cells cultured with complete RPMI media. Graph pad was used to calculate IC50 values.
- Osteoarthritis was induced chemically by an intra-articular (I .A.) injection of 3 mg of monosodiumiodoacetate (MIA) (in 25 pL saline) into the right hind limb knee joint of the rat given under isoflurane anesthesia. While under anesthesia, ophthalmic ointment was applied to both eyes. The day of I.A. injection of MIA was counted as Day 0.
- I .A. intra-articular
- MIA monosodiumiodoacetate
- Baseline dynamic weight bearing were measured for all rats. Body weight (BW) was also measured at the same time. Rats were anesthetized and MIA injected into the right Knee joint through the middle of the patellar tendon approximately perpendicular to the tibia (Intra-articular (I.A.)). Dose level for I.A. injection of MIA was selected based on previous literature report in rodents (Bove et al.: Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage. 2003 Nov;11 (11):821-830). Animals showing a significant weight bearing difference between the MIA injected limb (right) and the healthy limb (left) were assigned to the study. Randomization was done based on both baseline DWB and BW (two variables randomization).
- Dynamic Weight Bearing was evaluated using the BioSeb® automated DWB system according to the manufacturer’s manual. A two-minute recording was done for each rat. Analysis of dynamic weight bearing data was done off-line using the BioSeb® software. The system automatically calculated the weight borne by each limb and the tail. Body weight was measured for each rat immediately before the DWB for each time of testing. DWB measurement was done at different time points as per schedule in Study Design. Total distance travelled was also noted during DWB data analysis.
- Group 1-2 rats received intravenous (IV) injections of vehicle and Group 3-7 rats received IV injections with the test items at designated doses once on Day 3 as depicted in the table below.
- Group 8 rats received oral gavage dosing with dexamethasone once daily from Day 3-21 as depicted in the table below.
- IV Intravenous (tail vein); PO: oral gavage; QD-once daily
- Treated animals were observed for any clinical signs during the study.
- DWB was analysed on Days 3, 6, 14 and 21 .
- Joint diameter was measured using a caliper on the right knee joint (medio-laterally) on days 3, 6, 14 and 21 .
- PK bleeds from 5 rats per group were taken using standard procedures on alternative days.
- PetML119 from different doses, showed similar half-life (around 70 hrs) while PetML122 showed an extended half-life (around 10.5 days), see figure 12.
- PetML119 (1.5 mg/kg) Intravenous infusion.
- a reversible urate crystal synovitis model was used to induce an experimental acute synovitis.
- a sodium urate crystal suspension was prepared at a concentration of 10 mg/mL.
- General anaethesia was induced via an intra-articular injection of propofol. Alternate stifle joints were used in each period.
- Vehicle and test item (PetMLI 19/PetML122) treatment administrations were performed three days before acute synovitis induction (at Day-3).
- Meloxicam treatment administrations were performed right before acute synovitis induction (at T-0.5h).
- Treatment administrations were designed to obtain maximum treatment effect at the time of maximal induced lameness (i.e. 2 h-3 h after acute synovitis induction).
- Sandwich ELISA to identify potential anti-Drug Antibodies (ADA) in the serum generated after treatment with our fusion protein in-vivo were set up as follows:
- VLS visual lameness score
- VF vertical force
- the VF values were obtained as the limb is placed on the force plate.
- the dogs passed at least 5 times in the path of the force plate in order to obtain 3 interpretable values for the hind limb, to calculate the mean force of the limb.
- the ratio between the force applied after treatment and the force applied on Predose (reference force) of the same hind limb was referred to as the ‘lameness ratio.’ This parameter describes the force applied by the induced limb in relation to the force applied in the absence of inflammation. If severe lameness with no weight bearing is observed during walking phase, the vertical force was not measured and the lameness ratio was considered equal to zero.
- the combined lameness visual score was considered as the sum of the standing and walking phase scores.
- PetML119 and PetML122 exhibit improved efficacy to the gold standard for acute pain, Meloxicam (Figure 14). Furthermore, PetML119 and PetML122 have the additional benefit of only requiring a single dose for extended pain relief. In contrast, Meloxicam or other existing treatments require daily administration which reduces compliance and increases stress to the animal.
- Sandwich ELISA to measure pK values are as described in Example 11 above.
- PetML122 showed an extended half-life (around 19 days) in comparison to the half-life of PetML1 19 (around 4 days), see figure 15.
- SEQ ID NO. 1 canine p75NTR protein
- ECD is underlined SEQ ID NO. 2 canine p75NTR nucleic acid sequence
- SEQ ID NO. 4 feline p75NTR nucleic acid sequence ATGGACGGGCCGCGCCCGCTGCTGCTGCTGTTGCCGCTGCTCCTGGGGGTGTCCCTTGGAGGT
- SEQ ID NO. 7 canine p75NTR protein ECD
- the wt ECD region includes the stalk region (underlined) and alpha and gamma secretase cleavage 3’ of the stalk region (in bold)
- SEQ ID NO. 8 canine p75NTR ECD nucleic acid sequence
- SEQ ID NO. 9 canine ECD of p75NTR stalk region protein
- SEQ ID NO. 10 canine ECD of p75NTR stalk region nucleic acid sequence
- SEQ ID NO. 11 canine p75NTR ECD - canine IgGB wt Fc protein fusion
- SEQ ID NO. 12 canine p75NTR ECD- canine IgGB wt Fc nucleic acid sequence
- SEQ ID NO. 13 canine p75NTR ECD - canine Fc YTE protein fusion
- SEQ ID NO. 14 canine p75NTR ECD - Fc YTE nucleic acid sequence
- SEQ ID NO. 34 portion of canine ECD as used in the fusion constructs (without stalk and without alpha and gamma secretase cleavage 3’ of the stalk region)
- SEQ ID NO. 35 canine p75NTR ECD nucleic acid sequence as used in the fusion constructs (without stalk and without alpha and gamma secretase cleavage 3’ of the stalk region)
- SEQ ID NO. 36 bovine p75 NTR protein
- SEQ ID NO. 40 feline p75NTR ECD- feline lgG1 wt Fc nucleic acid sequence
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022369106A AU2022369106A1 (en) | 2021-10-21 | 2022-10-21 | Proteins comprising the extracellular domain of p75ntr |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2115098.2 | 2021-10-21 | ||
GBGB2115098.2A GB202115098D0 (en) | 2021-10-21 | 2021-10-21 | Therapeutic molecules |
US17/506,876 | 2021-10-21 | ||
US17/506,876 US11608371B1 (en) | 2021-10-21 | 2021-10-21 | Therapeutic molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023067358A1 true WO2023067358A1 (en) | 2023-04-27 |
Family
ID=84084427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2022/052692 WO2023067358A1 (en) | 2021-10-21 | 2022-10-21 | Proteins comprising the extracellular domain of p75ntr |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2022369106A1 (en) |
WO (1) | WO2023067358A1 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8362208B2 (en) | 2005-12-16 | 2013-01-29 | Glaxo Group Limited | Immunoglobulins |
WO2013136078A1 (en) | 2012-03-14 | 2013-09-19 | Levicept Ltd | Therapeutic use of p75ntr neurotrophin binding protein |
WO2015040398A1 (en) * | 2013-09-18 | 2015-03-26 | Levicept Ltd | Fusion protein |
WO2016146841A1 (en) * | 2015-03-19 | 2016-09-22 | Levicept Limited | P75ntr -fc fusion protein |
WO2019177690A1 (en) | 2018-03-12 | 2019-09-19 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
WO2020142625A2 (en) | 2019-01-03 | 2020-07-09 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
WO2020191289A1 (en) * | 2019-03-20 | 2020-09-24 | Kindred Biosciences, Inc. | Ngf antagonists for medical use |
-
2022
- 2022-10-21 WO PCT/GB2022/052692 patent/WO2023067358A1/en active Application Filing
- 2022-10-21 AU AU2022369106A patent/AU2022369106A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8362208B2 (en) | 2005-12-16 | 2013-01-29 | Glaxo Group Limited | Immunoglobulins |
WO2013136078A1 (en) | 2012-03-14 | 2013-09-19 | Levicept Ltd | Therapeutic use of p75ntr neurotrophin binding protein |
WO2015040398A1 (en) * | 2013-09-18 | 2015-03-26 | Levicept Ltd | Fusion protein |
WO2016146841A1 (en) * | 2015-03-19 | 2016-09-22 | Levicept Limited | P75ntr -fc fusion protein |
WO2019177690A1 (en) | 2018-03-12 | 2019-09-19 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
WO2020142625A2 (en) | 2019-01-03 | 2020-07-09 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
WO2020191289A1 (en) * | 2019-03-20 | 2020-09-24 | Kindred Biosciences, Inc. | Ngf antagonists for medical use |
Non-Patent Citations (12)
Title |
---|
"Antibody Engineering", vol. 1, 2, 2010, SPRINGER-VERLAG |
"Therapeutic Monoclonal Antibodies: From Bench to Clinic", 2009, WILEY |
BARKER ET AL., JOURNAL OF PAIN RESEARCH, vol. 13, 2020, pages 1223 - 1241 |
BOVE ET AL.: "Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis", OSTEOARTHRITIS CARTILAGE, vol. 11, no. 11, November 2003 (2003-11-01), pages 821 - 830, XP002340117, DOI: 10.1016/S1063-4584(03)00163-8 |
DATABASE UniProt [online] 21 March 2012 (2012-03-21), "SubName: Full=Nerve growth factor receptor {ECO:0000313|EMBL:JAA38273.1, ECO:0000313|Ensembl:ENSPTRP00000015928.5};", retrieved from EBI accession no. UNIPROT:H2QDD4 Database accession no. H2QDD4 * |
DENK ET AL., ANNUAL REVIEW OF NEUROSCIENCE, vol. 40, 2017, pages 307 - 325 |
ENOMOTO ET AL., VET REC, vol. 184, no. 1, 5 January 2019 (2019-01-05), pages 23 |
GREENSAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS |
L.M. BERGERON ET AL., VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, vol. 157, 2014, pages 31 - 41 |
TANG ET AL., VET. IMMUNOL. IMMUNOPATHOL., vol. 80, 2001, pages 259 - 270 |
TOUTIAN ET AL., J. VET. PHARMACOL. THERAP., vol. 24, 2001, pages 43 - 55 |
WHO DRUG INFORMATION, vol. 32, no. 4, 2018, pages pg568 |
Also Published As
Publication number | Publication date |
---|---|
AU2022369106A1 (en) | 2024-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210122805A1 (en) | Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS | |
US10858430B2 (en) | Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof | |
JP7417277B2 (en) | Ultra-long-acting insulin-FC fusion protein and methods of use | |
CN104508133B (en) | Method for producing monomer and multimeric molecule and application thereof | |
RU2764559C2 (en) | MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | |
TWI791006B (en) | Fusion protein comprising BDNF | |
KR20140041533A (en) | Therapeutic canine immunoglobulins and methods of using the same | |
CN104508132A (en) | Method for producing soluble FcR as FC-fusion with inert immunoglobulin FC-region and uses thereof | |
US20230002466A1 (en) | Engineered interleukin-2 receptor beta agonists | |
TW201843179A (en) | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same | |
JP2020536552A5 (en) | ||
CA3084602A1 (en) | Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment | |
CA2997263A1 (en) | Apoa-1 fusion polypeptides and related compositions and methods | |
CA3110498A1 (en) | Enpp1 polypeptides and methods of using same | |
CN106957365B (en) | Monoclonal antibody FnAb8 and application thereof | |
AU2017322483A1 (en) | Methods and compositions for treatment of lafora disease | |
US11608371B1 (en) | Therapeutic molecules | |
WO2023067358A1 (en) | Proteins comprising the extracellular domain of p75ntr | |
JP2023543262A (en) | Canine antibody variants | |
US20210163614A1 (en) | Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof | |
CN106957364B (en) | Monoclonal antibody FnAb12 and application thereof | |
EP4166574A1 (en) | Fusion protein containing erythropoietin polypeptide | |
US20240059777A1 (en) | Mutations in canine antibody constant regions | |
JP2023551194A (en) | bovine antibody variants | |
JP2024503212A (en) | Mutations in the constant region of feline antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22800315 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022369106 Country of ref document: AU Ref document number: AU2022369106 Country of ref document: AU Ref document number: 809707 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2022369106 Country of ref document: AU Date of ref document: 20221021 Kind code of ref document: A |